TransMedics to Report First Quarter 2022 Financial Results on May 3, 2022
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will announce its first-quarter 2022 financial results on May 3, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will announce its first-quarter 2022 financial results on May 3, 2022, after market close. A conference call to discuss these results will take place at 5:00 p.m. ET. Investors can access the call by dialing (844) 200-6205 domestically or (929) 526-1599 internationally, using Conference ID: 215877. The company aims to enhance organ preservation and assessment for transplants, addressing vital needs in heart, lung, and liver failure treatments.
Positive
- Leading position in portable organ perfusion technology.
- Focus on increasing organ utilization for transplant needs.
Negative
- None.
Details
News Market Reaction – TMDX
The recorded move for TMDX in the trading session of this news was +1.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter of 2022 after market close on Tuesday, May 3, 2022. The TransMedics management team will host a corresponding conference call beginning at 5:00 p.m. ET / 2:00 p.m. PT.
Investors interested in listening to the conference call may do so by dialing (844) 200-6205 for domestic callers or (929) 526-1599 for international callers, followed by Conference ID: 215877. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-first-quarter-2022-financial-results-on-may-3-2022-301528544.html
SOURCE TransMedics Group, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.